Mapi Posters

2016. AAN Annual Meeting – Is Health-Related Quality of Life an Important Evaluation Criterion in Drug Development of Multiple Sclerosis (MS) Products? A Review of Labels of MS Products Approved the FDA and the EMA

Acquadro C, Perret C, Regnault A. Is Health-Related Quality of Life an Important Evaluation Criterion in Drug Development of Multiple Sclerosis (MS) Products? A Review of Labels of MS Products Approved the FDA and the EMA. . Presented at: American Academy of Neurology (AAN) 68th Annual Meeting; April 17, 2016; Vancouver, Canada.